Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales flat at $8.6 billion in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
2Q Revenues: $18.8 billion (+2%)
2Q Earnings: $3.8 billion (-4%)
YTD Revenues: $36.6 billion (+2%)
YTD Earnings: $8.2 billion (-2%)
Comments: Worldwide Pharmaceutical sales were flat at $8.6 billion in the quarter. Domestic sales were down 3%; international sales increased 3%, which reflected an operational increase of 6% and a negative currency impact of 3%. Remicade sales were down 14% to $1.5 billion. Zytiga sales were down 7% to $558 million. INVOKANA sales were down 23% to $295 million. DARZALEX sales were $299 million, up from $108 million in 2Q16. IMBRUVICA sales were $450 million, up 53%. Additional contributors to operational sales growth included STELARA, up 22% to $983 million and INVEGA SUSTENNA/XEPLION/TRINZA, up 12% to $629 million. During the quarter, the company completed the acquisition of Actelion Ltd., a biopharmaceutical company, for approximately $30 billion in cash.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters